Mundipharma-Purdue reach a new deal to in-licence from Esteve full global rights for novel first-in-class AS1 for the management of pain Blog Post

Mundipharma its independent associated company Purdue Pharma today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (AS1 o MR309/E-52862). In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs. 

 

Researchers froms IBEC and UB have collaborated in the definition of a new kind of indicators for bacterial virulence Blog Post

Researchers and the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona (UB) together with their collaborators from the University of Santiago de Compostela (USC), the Institute of Medical Microbiology and Hygiene (University of Lübeck) and German Center for Infection Research (DZIF) have determined a new kind of indicators for bacterial virulence which can help detect and preventing infection outbreaks caused by Escherichia coli.

 

Intelligent Pharma wins the award CaràcterEmpresa to Innovation in Catalonia Blog Post

Intelligent Pharma, a company based at the Barcelona Science Park  (PCB), has won the Premi CaràcterEmpresa award in the category of Innovation among 14 companies from around Catalonia and has been selected to take part in the nation-wide final phase, that will take place this coming June. The CaràcterEmpresa awards are promoted by CaixaBank and by the Spanish Confederatiion of Business Organizations (CEOE) in the Catalan edition, also promoted by Foment del Treball, the institution representing the interests of Catalan industry and business.

Cebiotex opens a second crowdfunding round for the development of nanofiber tissues against cancer Blog Post

After having succesfully closed a first crowfunding round of 300,000 euros in just 11 days, Cebiotex, a spin-off of the Universitat Politècnica de Catalunya (UPC) and the Sant Joan de Déu-Barcelona Children’s Hospital, located at the Barcelona Science Park (PCB), has launched a second round of  300,000 euros, managed, once more, by European biotech crowdfunding platform CapitalCell. The company will allocate the resources obtained to expedite the development of an innovative system to administer antitumor drugs – a biodegradable nanofiber tissue for the local treatment of cancer- while ensuring that these new drugs are made available not only for adult patients but also for pediatric oncological patients 

 

Mind the Byte and Sequentia take part in a trade mission in Massachusetts Blog Post

Mind the Byte and Sequentia Biotech, both based at the Barcelona Science Park (PCB), have been two of the 10 Catalan companies that participated last week in a trade mission in the state of Massachusetts (US) to search for business opportunities in the fields of digital health and big data applied to life sciences. The trade mission was organized by the Government of Catalonia through ACCIÓ, the agency for business competitiveness, and Biocat coinciding with Bio-IT World Conference & Expo, one of the largest and most important events in the US in the field of ICTs in the health sector.  

 

The 14th edition of Live Research broke attendance records Blog Post

A total of 1711 visitors, 580 more than last year, participated in the 2015 Live Research held at CosmoCaixa Barcelona to learn about the leading projects being carried out in eleven research centers and university throughout Catalonia. The fair was organized by the Barcelona Science Park (PCB) and Obra Social ”la Caixa”, with the support of the Barcelona City Council and the collaboration of the University of Barcelona (UB) 

 

STAT-Diagnostica closes a round of investment worth 25 million euros Blog Post

Medical diagnostics company  STAT-Diagnostica, located at the Barcelona Science Park (PCB), has closed a Series C financing round totaling 25 million Euros/28.5 million USD. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system. Led by new investor Gilde Healthcare, the financing round also drew participation from existing investors, including Kurma Partners, Ysios Capital, Idinvest Partners, Boehringer Ingelheim Venture Fund, Caixa Capital Risc and Axis.

 

Intelligent Pharma receives the TECNIO accreditation Blog Post

Yesterday, 7 April, the Government of Catalonia presented the new TECNIO accreditation in an event led by the Minister of Business and Knowledge, Jordi Baiget, that brought together nearly 300 people from the Catalan scientific and technological community at the Mediapro building. The seal identifies in a first phase 54 entities that offer the most innovative technologies to help business create products, processes or services. Intelligent Pharma, specialized in computational chemistry services for the pharmaceutical and biotechnological industry, based at the Parc Científic de Barcelona, was one of the companies honored to have received this accreditation. 

 

Identification of a new protein essential for ovule and sperm formation Blog Post

Scientists at he Institute for Research in Biomedicine (IRB Barcelona) –headed by ICREA researcher Angel R. Nebreda– discover a crucial protein for meiosis, the cell division process that gives rise to sex cells. Without the RingoA protein, both male and female mice are sterile. Published in Nature Communications, the results could pave the way for the development of male contraceptives.